Quick Take
Satsuma Pharmaceuticals (STSA) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is focused on the development of a treatment of acute migraine headache.
STSA has begun Phase 3 trials and expects to publish initial topline results by the second half of 2020.
Company & Technology
San Francisco, California-based Satsuma Pharmaceuticals was founded in 2016 to develop and commercialize an acute treatment for migraine headaches.
Management is headed by co-founder, CEO and Director John Kollins, who was